The FDA has granted Breakthrough Therapy designation to Legacy Healthcare's investigational topical treatment CINAINU for moderate-to-severe alopecia areata from age two. A pediatric trial showed statistically significant hair-regrowth benefits, although the primary efficacy analysis included only 62 of 107 randomized patients.
Abram Scientific has received a DARPA contract worth up to $8.3 million to advance CoagCare, a portable blood coagulation testing platform designed to provide results in under 10 minutes. The award supports military and civilian development, but regulatory clearance and clinical performance validation remain outstanding.
Providence Medical Technology has announced FDA clearance for CORUS PCSS 3D-T, a porous titanium posterior cervical fusion implant. Its established platform has randomized clinical evidence, but the new implant's incremental clinical benefit remains to be demonstrated.
TuHURA has secured a US patent covering TBS-2025 and related VISTA-targeting antibody designs through February 2042. The intellectual property expansion follows FDA clearance of an early-stage AML study, but clinical efficacy and commercialization remain unproven.
The FDA has accepted FYB206, a proposed biosimilar to Merck's Keytruda, for review, with a decision potentially due in the third quarter of 2027. Zydus and Formycon pursued a streamlined development programme without a comparative Phase 3 efficacy trial, but approval, patent clearance and commercial launch remain separate hurdles.
New Phase 3 AFFIRM data show 35.8% endoscopic remission and 36.6% ulcer-free endoscopy with subcutaneous Skyrizi at Week 24. The findings support regulatory applications for an alternative to intravenous induction, although differences in treatment allocation after Week 12 require careful interpretation.
Paradigm Therapeutics has received its second consecutive Prix Galien USA nomination for SD-101, an investigational whole-body epidermolysis bullosa cream. A new pediatric Phase 3 study offers another opportunity to establish efficacy after the earlier ESSENCE trial failed its primary endpoints.
Vantis Vascular has received FDA 510(k) clearance for a 6F version of its CrossFAST delivery system, expanding compatibility with intravascular imaging and calcium-modification devices. The November launch builds on encouraging early clinical experience, although comparative evidence remains limited.
CSQ Bio has established a surgical commercialization business and introduced INNESTO Rx, a bovine collagen powder scheduled for US sales in January 2027. The product uses an existing FDA-cleared device platform, but clinical differentiation, reimbursement and distribution economics remain unproven.
Avenzo's partner VelaVigo will disclose early human safety and efficacy findings for the Nectin-4/TROP2 antibody-drug conjugate VBC103 at ESMO Asia 2026. The presentation could clarify the clinical potential of dual-antigen targeting, while a separate United States study advances in urothelial cancer.